Search results for "Neutralizing"

showing 10 items of 43 documents

Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.

2017

Coxsackie B viruses are among the most common enteroviruses, causing a wide range of diseases. Recent studies have also suggested that they may contribute to the development of type 1 diabetes. Vaccination would provide an effective way to prevent CVB infections, and the objective of this study was to develop an efficient vaccine production protocol for the generation of novel CVB vaccines. Various steps in the production of a formalin-inactivated Coxsackievirus B1 (CVB1) vaccine were optimized including the Multiplicity Of Infection (MOI) used for virus amplification, virus cultivation time, type of cell growth medium, virus purification method and formulation of the purified virus. Safety…

0301 basic medicineformalin inactivationviruksetvirusesDrug Evaluation PreclinicalPolysorbatesmedicine.disease_causeAntibodies ViralMice0302 clinical medicineMultiplicity of infectionImmunogenicity VaccinevaccineChlorocebus aethiops030212 general & internal medicineImmunogenicityVaccinationVaccinationInfectious Diseasescoxsackievirus B1Molecular MedicineFemaleUltracentrifugeVirus CultivationCoxsackievirus InfectionsBiologyCoxsackievirusta3111VirusMicrobiology03 medical and health sciencesFormaldehydemedicineAnimalsCVB1Vero CellscoxsackievirusGeneral VeterinaryGeneral Immunology and Microbiologyrokotteetta1182Public Health Environmental and Occupational HealthViral Vaccinesbiology.organism_classificationVirologyAntibodies NeutralizingVirus CultivationEnterovirus A HumanDisease Models Animal030104 developmental biologyVaccines Inactivatedvirus purificationEnterovirusVaccine
researchProduct

N‐Terminal Modification of Gly‐His‐Tagged Proteins with Azidogluconolactone

2021

Site-specific protein modifications are vital for biopharmaceutical drug development. Gluconoylation is a non-enzymatic, post-translational modification of N-terminal HisTags. We report high-yield, site-selective in vitro α-aminoacylation of peptides, glycoproteins, antibodies, and virus-like particles (VLPs) with azidogluconolactone at pH 7.5 in 1 h. Conjugates slowly hydrolyse, but diol-masking with borate esters inhibits reversibility. In an example, we multimerise azidogluconoylated SARS-CoV-2 receptor-binding domain (RBD) onto VLPs via click-chemistry, to give a COVID-19 vaccine. Compared to yeast antigen, HEK-derived RBD was immunologically superior, likely due to observed diffe…

Models MolecularAzidesCOVID-19 VaccinesGlycosylationvirusesGlycineGluconatesBiochemistryLactoneschemistry.chemical_compoundAntigenHumansHistidineVaccines Virus-Like ParticleSeroconversionMolecular Biologychemistry.chemical_classificationMolecular StructurebiologyChemistryOrganic ChemistryAntibodies NeutralizingBiopharmaceuticalBiochemistrybiology.proteinClick chemistryMolecular MedicineAntibodyGlycoproteinConjugateChemBioChem
researchProduct

The inhibitors - a challenge for the management of patients with hereditary haemophilia A.

2018

Abstract Introduction. Our research strategy was aimed at evaluating the possible implication of the type of factor VIII product administered as substitution treatment to haemophilia A patients in the occurrence of inhibitors and their consequences on the management. Methods. Scientific articles from July 2015 to July 2017 were searched using the PubMed and PubMed Central databases. The used search terms included “haemophilia A”, “inhibitors”, “plasma-derived factor VIII” and “recombinant factor VIII”. Results. The risk factors for inhibitors occurrence may be patients-related (genetic and nongenetic) and treatment-related. The possibility of a correlation between the increased purity of fa…

medicine.medical_specialtyBispecific antibodyHaemophilia A030204 cardiovascular system & hematologyBioinformaticsHemophilia AFactor VIII productRecombinant factor viii03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesinhibitorsmedicineHumansInternal medicineFactor VIIIbusiness.industryhaemophilia amedicine.diseaseplasma-derived factor viiiRC31-1245Recombinant Proteinsneutralizing alloantibodiesSearch termsCoagulationrecombinant factor viiibusiness030215 immunologyRomanian journal of internal medicine = Revue roumaine de medecine interne
researchProduct

Seroprevalence of Aichi Virus in a Spanish Population from 2007 to 2008

2010

ABSTRACT Viruses are among the most common causes of acute gastroenteritis. In recent years, new viruses causing outbreaks of acute gastroenteritis have been described. Among these, Aichi virus was identified in Japan in 1989. Aichi virus belongs to the Kobuvirus genus in the family Picornaviridae . This virus has been detected in outbreaks of gastroenteritis associated with oyster consumption and in pediatric stool samples, but little is known about its epidemiology or pathogenesis. In the present study, the prevalence of antibodies to Aichi virus in a Spanish population was determined between 2007 and 2008 by using an enzyme-linked immunosorbent assay (ELISA). As in previous studies, a hi…

AdultMaleMicrobiology (medical)KobuvirusAdolescentvirusesClinical BiochemistryImmunologyEnzyme-Linked Immunosorbent AssayAntibodies ViralVirusYoung AdultNeutralization TestsSeroepidemiologic StudiesHumansImmunology and AllergySeroprevalenceChildNeutralizing antibodyAgedAged 80 and overPicornaviridae Infectionsbiologyvirus diseasesOutbreakMiddle Agedbiology.organism_classificationAntibodies NeutralizingVirologyTiterSpainKobuvirusChild Preschoolbiology.proteinFemaleMicrobial ImmunologyAntibodyAichi virusClinical and Vaccine Immunology
researchProduct

Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS‐CoV‐2 neutralizing activity of sera

2020

Purpose: Assessment of commercial SARS-CoV-2 immunoassays for their capacity to provide reliable information on sera neutralizing activity is an emerging need. We evaluated the performance of two commercially-available lateral flow immunochromatographic assays (LFIC) (Wondfo SARS-CoV-2 Antibody test and the INNOVITA 2019-nCoV Ab test) in comparison with a SARS-CoV-2 neutralization pseudotyped assay for COVID-19 diagnosis in hospitalized patients, and investigate whether the intensity of the test band in LFIC associates with neutralizing antibody (NtAb) titers. Patients and Methods: Ninety sera were included from 51 patients with moderate to severe COVID-19. A green fluorescent protein (GFP)…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Green Fluorescent ProteinsAntibodies ViralNeutralizing antibodiesNeutralizationSARS‐CoV‐2Green fluorescent protein03 medical and health sciencesCOVID-19 Testing0302 clinical medicineCOVID‐19VirologyLateral flow 16 immunochromatographic assaysHumansMedicineImmunochromatographic Assays030212 general & internal medicineNeutralizing antibodyResearch ArticlesImmunoassaybiologybusiness.industrySARS-CoV-2COVID-19biology.organism_classificationAntibodies NeutralizingVirologyTiterInfectious DiseasesImmunoglobulin MVesicular stomatitis virusImmunoglobulin GSpike Glycoprotein Coronavirusbiology.proteinlateral flow immunochromatographic assays030211 gastroenterology & hepatologyLteral flow immunochromatographic assaysAntibodybusinessResearch Article
researchProduct

A novel rat CVB1-VP1 monoclonal antibody 3A6 detects a broad range of enteroviruses

2018

AbstractEnteroviruses (EVs) are common RNA viruses that cause diseases ranging from rash to paralytic poliomyelitis. For example, EV-A and EV-C viruses cause hand-foot and mouth disease and EV-B viruses cause encephalitis and myocarditis, which can result in severe morbidity and mortality. While new vaccines and treatments for EVs are under development, methods for studying and diagnosing EV infections are still limited and therefore new diagnostic tools are required. Our aim was to produce and characterize new antibodies that work in multiple applications and detect EVs in tissues and in vitro. Rats were immunized with Coxsackievirus B1 capsid protein VP1 and hybridomas were produced. Hybr…

Models Molecular0301 basic medicineBiolääketieteet - BiomedicineProtein Conformationmedicine.drug_classImmunoelectron microscopylcsh:MedicineEnzyme-Linked Immunosorbent AssayCoxsackievirusmedicine.disease_causeMonoclonal antibodyenterovirusesArticleEpitopeEpitopesMice03 medical and health sciencesProtein DomainsEnterovirus InfectionsmedicineantibodiesAnimalsHumanslcsh:ScienceMultidisciplinary030102 biochemistry & molecular biologybiologyPolioviruslcsh:Rvasta-aineetAntibodies Monoclonalbiology.organism_classificationAntibodies NeutralizingImmunohistochemistryVirologyEnterovirus B HumanRats3. Good healthenterovirukset030104 developmental biologyKasvibiologia mikrobiologia virologia - Plant biology microbiology virologybiology.proteinImmunohistochemistrylcsh:QCapsid ProteinsAntibodyClone (B-cell biology)Protein BindingScientific Reports
researchProduct

CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in…

2018

Background & Aims Pancreatic ductal adenocarcinoma (PDAC) is frequently accompanied by excruciating pain, which has been associated with attraction of cancer cells and their invasion of intrapancreatic sensory nerves. Neutralization of the chemokine CCL2 reduced cancer-associated pain in a clinical trial, but there have been no systematic analyses of the highly diverse chemokine families and their receptors in PDAC. Methods We performed an open, unbiased RNA-interference screen of mammalian chemokines in co-cultures of mouse PDAC cells (K8484) and mouse peripheral sensory neurons, and confirmed findings in studies of DT8082 PDAC cells. We studied the effects of chemokines on migration of PD…

0301 basic medicineReceptors CCR7ChemokineReceptors CXCR3Sensory Receptor Cellsendocrine system diseasesC-C chemokine receptor type 7CXCR303 medical and health sciencesChemokine receptor0302 clinical medicineCell MovementCell Line TumorGanglia SpinalPancreatic cancermedicineAnimalsHumansCXCL10AnalgesicsChemokine CCL21Hepatologybiologybusiness.industryGastroenterologyCancer Painmedicine.diseaseAntibodies NeutralizingCoculture Techniquesdigestive system diseasesChemokine CXCL10Mice Inbred C57BLPancreatic Neoplasms030104 developmental biologyCancer cellCancer researchbiology.protein030211 gastroenterology & hepatologybusinessCarcinoma Pancreatic DuctalSignal TransductionCCL21Gastroenterology
researchProduct

The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs th…

2016

Phosphodiesterase 4 (PDE4) inhibitors serve to prevent degradation of the intracellular second messenger cAMP, resulting in broad anti-inflammatory effects on different cell types including immune cells. Agents that elevate cAMP levels via activation of adenylate cyclase have been shown to imprint a Th17-promoting capacity in dendritic cells (DCs). Therefore, we studied the potential of therapeutically relevant PDE inhibitors to induce a pronounced Th17-skewing capacity in DCs. Here we show that mouse bone marrow-derived (BM-) DCs when treated with the PDE4 inhibitor roflumilast (ROF, trade name: Daxas) in the course of stimulation with LPS (ROF-DCs) evoked elevated IL-17 levels in cocultur…

Cyclopropanes0301 basic medicineT cellImmunologyAnti-Inflammatory AgentsAminopyridinesStimulationBiologyLymphocyte ActivationInterleukin-23Mice03 medical and health sciencesTh2 Cells0302 clinical medicineImmune systemHypersensitivitymedicineAnimalsImmunology and AllergyNeutralizing antibodyProtein kinase ACells CulturedRoflumilastPharmacologyMice Inbred BALB CDendritic CellsInterleukin-10Cell biologyMice Inbred C57BLInterleukin 10030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisBenzamidesImmunologybiology.proteinTh17 CellsPhosphodiesterase 4 InhibitorsInterleukin 17medicine.drugInternational Immunopharmacology
researchProduct

FRI0030 Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis

2016

Background TNF-α neutralizing molecules represent one of the most efficient therapeutic approaches to control inflammation in rheumatoid arthritis (RA). The widespread distribution in the body induces the inhibition of TNF-α in all the tissues, requesting the use of high dose of this expensive drug. Another problem that has not yet been solved in the management of RA patients is how to reduce and possibly avoid the side effects, particularly the increased risk of common and opportunistic infections, which may be associated with long-term administration of these therapeutic drugs. Objectives The aim of the present investigation was to show that a recombinant protein obtained by fusing a syno…

rheumatoid arthritisPathologymedicine.medical_specialtyImmunologyArthritisInflammationImmunofluorescenceGeneral Biochemistry Genetics and Molecular BiologyRheumatologyIn vivoAdalimumabmedicineImmunology and AllergyNeutralizing antibodyantigen induced arthritismedicine.diagnostic_testbiologybusiness.industrytarget therapyantigen induced arthritirheumatoid arthritimedicine.diseaseRheumatoid arthritisImmunologyrheumatoid arthritis; antigen induced arthritis; target therapy; immunotherapybiology.proteinTumor necrosis factor alphaimmunotherapymedicine.symptombusinessmedicine.drug
researchProduct

Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice

2015

Abstract Background Therapeutic vaccination is a novel treatment approach for chronic hepatitis B, but only had limited success so far. We hypothesized that optimized vaccination schemes have increased immunogenicity, and aimed at increasing therapeutic hepatitis B vaccine efficacy. Methods Modified Vaccinia virus Ankara (MVA) expressing hepatitis B virus (HBV) antigens was used to boost protein-prime vaccinations in wildtype and HBV-transgenic (HBVtg) mice. Results Protein-prime/MVA-boost vaccination was able to overcome HBV-specific tolerance in HBVtg mice with low and medium but not with high antigenemia. HBV-specific antibody titers, CD8+ T-cell frequencies and polyfunctionality inverse…

CD4-Positive T-Lymphocytes0301 basic medicineHBsAgHepatitis B vaccineImmunization SecondaryMice TransgenicVaccinia virusCD8-Positive T-Lymphocytesmedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundAntigenNeutralization TestsImmune ToleranceAnimalsMedicineHepatitis B VaccinesHepatitis B e AntigensHepatitis B AntibodiesHepatitis B virusHepatitis B Surface AntigensGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational Healthvirus diseasesHepatitis BHepatitis Bmedicine.diseaseAntibodies NeutralizingHepatitis B Core AntigensVirologyMice Inbred C57BLVaccination030104 developmental biologyInfectious DiseaseschemistryImmunologyMolecular MedicineVacciniabusinessVaccine
researchProduct